Acadia Pharma GAAP EPS of $0.28 misses by $0.02, revenue of $231.04M beats by $7.24M
by
Contributor since / Followers
Contributor since / Followers
10 months ago
- Acadia Pharma press release (NASDAQ:ACAD): Q4 GAAP EPS of $0.28 misses by $0.02.
- Revenue of $231.04M (+69.3% Y/Y) beats by $7.24M.
-
Full Year 2024 Financial Guidance
- DAYBUE net product sales in the range of $370 to $420 million.
- NUPLAZID net product sales in the range of $560 to $590 million.
- GAAP R&D expense in the range of $305 to $325 million.
- GAAP SG&A expense in the range of $455 to $480 million.